Eli Lilly has entered into an agreement with the U.S. government to supply 150,000 doses of bebtelovimab for $275 million. The drug is intended to treat mild to moderate COVID-19 in adults and children 12 years of age and older. Delivery is due no later than August 5, 2022. The agreement also includes an option for 350,000 doses, to be exercised no later than September 14, 2022.